Substituted quinazolinamine compounds for the treatment of cancer
US7989461B2 · kind B2 · utility
6Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2006 |
| Grant date | Aug 2, 2011 |
| Priority date | — |
| Expiry date | Dec 20, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula Iwherein R1 isand A1, A2, A3, A4, X, Z, Z′, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.